AI in oncology and society sparks debate among experts and tech leaders

Medical professionals and technology leaders are debating the role of artificial intelligence in oncology and its broader societal impact. Dr. Matthew Matasar and Dr. Arturo Loaiza-Bonilla discussed the “embracing the dialectic” moment in oncology, where deep optimism regarding AI’s potential in drug discovery meets professional uncertainty. They noted that AI is already reshaping the field, citing a drug currently in phase 3 trials for pulmonary fibrosis that was developed using AI to detect a novel target and design a molecule.

In a separate perspective, OpenAI CEO Sam Altman stated that curing cancer may not be sufficient to win over public skeptics. While acknowledging the importance of medical breakthroughs, Altman argued that the tech industry must also demonstrate how AI can “enable a boom in creativity and entrepreneurship” to address growing public concerns regarding job disruption and autonomy. This contrasts with Anthropic CEO Dario Amodei, who previously suggested that actual medical cures are necessary to move past the “cliché” of AI promises.